Jaguar Health Seeks Approval for Series Q Exchange, Warrant Repricing
Jaguar Health, Inc. will hold a Special Meeting of Stockholders on September 4, 2026, to vote on several key proposals. These include approving the issuance of common stock upon the exchange of Series Q Preferred Stock, which could lead to substantial dilution for existing shareholders, and the repricing of Investor Warrants to a significantly lower exercise price of $1.00 per share. Additionally, shareholders will vote on increasing the shares authorized for the 2014 Stock Incentive Plan to 14% of fully diluted common stock. All proposals require shareholder approval under Nasdaq Listing Rule 5635(d).
Key Highlights
- Special Meeting on September 4, 2026, to approve equity-related proposals.
- Proposal 1: Approve issuance of Common Stock for Series Q Preferred Stock exchange to accredited investors.
- Proposal 1: Potential issuance of up to 7.91 million shares, representing 62.0% dilution at $2.50 exchange price.
- Proposal 1: Maximum potential dilution of 90.2% of outstanding common stock at $0.50 exchange price.
- Proposal 2: Approve repricing of 60,781 Investor Warrants from $35.00-$266.44 to $1.00 exercise price.
- Proposal 2: Warrants also entitle investors to 682,661 shares from Series O Preferred Stock Dividend.
- Proposal 3: Approve increasing 2014 Stock Incentive Plan shares to 14% of fully diluted common stock.
- All proposals require shareholder approval under Nasdaq Listing Rule 5635(d).
Price Impact
More from JAGX
Jaguar Health Registers 5.52M Shares for Resale Following Recent Financing
Jaguar Health Subsidiary Signs New Manufacturing Agreement
Jaguar Health Completes Series O Preferred Stock Conversion; 4.86M Common Shares Outstanding